X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RV-1770 is an innovative mRNA-based vaccine formulation with a unique AI-enhanced design using the sequence of the recent RSV clinical isolate. It demonstrated immunogenic responses and neutralization against both type A and B strains of RSV in preclinical cotton rat studies.
Lead Product(s): RV-1770
Therapeutic Area: Infections and Infectious Diseases Product Name: RV-1770
Highest Development Status: IND EnablingProduct Type: Vaccine
Recipient: RNAimmune
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
STP707 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively, formulated in nanoparticles with a Histidine-Lysine Co-Polymer (HKP+H) peptide as the carrier, used for the treatment of Multiple Solid Tumors.
Lead Product(s): STP707
Therapeutic Area: Oncology Product Name: STP707
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
The partnership accelerates EDIRNA's proprietary Edit-to-Cure Therapeutics™ platform for RNA-Editing therapeutics, targeting diseases with high unmet clinical needs.
Lead Product(s): RNA-editing Therapeutic
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: EDIRNA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 05, 2023
Details:
STP705, is a small interfering RNA therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock TGF-β1 and COX-2 gene expression, which being investigated for Squamous Cell Carcinoma in situ.
Lead Product(s): STP705
Therapeutic Area: Oncology Product Name: STP705
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2023
Details:
STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock TGF-β1 and COX-2 gene expression, which being investigated for Abdominoplasty.
Lead Product(s): STP705
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: STP705
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
STP122G, Sirnaomics' leading RNAi drug candidate, is a siRNA that targets Factor XI and first participant Dosed in a Phase I clinical trial for prevention and treatment of stroke after atrial fibrillation.
Lead Product(s): STP122G
Therapeutic Area: Hematology Product Name: STP122G
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
STP705 is a novel siRNA therapeutic, having dual-targeted inhibitory property and a polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-β1 and COX-2 gene expressions. It is being investigated for non-melanoma skin cancers.
Lead Product(s): STP705
Therapeutic Area: Oncology Product Name: STP705
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
STP707 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively, formulated in nanoparticles with a Histidine-Lysine Co-Polymer (HKP+H) peptide as the carrier.
Lead Product(s): STP707
Therapeutic Area: Oncology Product Name: STP707
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-β1 and COX2 gene expression.
Lead Product(s): STP705
Therapeutic Area: Oncology Product Name: STP705
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-β1 and COX-2 gene expression.
Lead Product(s): STP705
Therapeutic Area: Nutrition and Weight Loss Product Name: STP705
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
